- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01482052
Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis
January 11, 2013 updated by: JN-International Medical Corporation
A Double-Blind, Randomized, Controlled, Two Arm Phase 1 Clinical Trial of the Safety and Immunogenicity of Group A, C, Y & W-135 Meningococcal Polysaccharide DT Conjugate Vaccine: NmVac4-A/C/Y/W-135-DT™
The purpose of this study is to evaluate the safety of a new conjugate vaccine, NmVac4-A/C/Y/W-135-DT, compared to the safety of a similar, licensed meningococcal A/C/Y/W-135-DT conjugate vaccine.
The investigators will also evaluate the production of antibodies to of NmVac4-A/C/Y/W-135-DT™ conjugate vaccine compared to the licensed vaccine, as a measure of vaccine effectiveness.
Study Overview
Status
Completed
Conditions
Detailed Description
Meningococcal disease is a potentially life-threatening bacterial infection.
The disease most commonly is expressed as either meningococcal meningitis, an inflammation of the membranes surrounding the brain and spinal cord, or meningococcemia, the presence of bacteria in the blood.
The most common symptoms include high fever, headache, neck stiffness, confusion, nausea, vomiting, lethargy, and rash.
If not treated the disease can progress rapidly and can lead to shock and death, often within hours of the onset of symptoms.
Neisseria meningitidis capsular polysaccharides are poor immunogens.
However, conjugation of bacterial polysaccharides to immunogenic carrier proteins generally results in conjugates that induce strong anti-polysaccharide T-helper cell dependent immune responses, creating a longer-lasting immune response and thus protection against meningococcal infection.
This study compares safety and antibody production induced by one intramuscular injection of either NmVac4-A/C/Y/W-135-DT or a licensed meningococcal A/C/Y/W-135-DT conjugate vaccine.
Participants will attend a screening visit up to 4 weeks prior to Day 0, then will attend study visits for 8 weeks.
There will be a study phone call at Days 2-3, then a post-study telephone call to subjects to assess safety at 26 weeks.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Hanford, California, United States, 93230
- Kings Cardiology Group
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Willing and able to give informed consent and comply with all aspects of the evaluation after the nature of the study is explain
- For the purpose of this study, a healthy volunteer is defined as healthy male or female, with no significant chronic conditions
- Age 18 to 50 years old
- Either gender. Abstinence or use of contraception during the eight weeks after vaccination will be required for non menopausal (< two years post-menopause) or non surgically sterile women
- Persons with antibody titer(s) of <2 µg/mL to serogroup(s) A, C, Y, or W-135 polysaccharides as measured by ELISA
Exclusion Criteria:
- Age less than 18 years or over 50 years.
- History of Guillain-Barré syndrome (GBS).
- Pregnancy or lactation.
- History of meningococcal meningitis.
- History of invasive (clinical or laboratory diagnosis) meningococcal disease.
- History of meningococcal meningitis vaccination.
- Screening laboratory abnormalities (in the opinion of the Investigator) that would raise safety concerns for participation in the study.
- Use of immunosuppressive drugs within 30 days prior to study enrollment, not including topical or inhaled steroids/cytotoxic agents.
- History of anaphylactic shock, asthma, urticaria, or other allergic or hypersensitivity reactions following vaccination.
- History of severe allergic disorders or autoimmune connective tissue disorders, including rheumatoid arthritis. A high sensitivity C-Reactive Protein (CRP) test at screening will be used as part of the assessment of autoimmune disorders by the Principal Investigator.
- Use of systemic antibiotics within 72 hours prior to study enrollment.
- History of cirrhosis.
- Positive results of testing for HepBsAg, Hepatitis C or HIV-1 or HIV-2 antibodies.
- Positive results of drug screen (amphetamine, THC, cocaine).
- Persons with antibody titer(s) of >2 µg/mL to serogroup (s) A, C, Y, or W 135 as measured by ELISA.
- Unable to understand all of the study requirements.
- Prisoners.
- Participation in a clinical trial in the last three months.
- History of any serious chronic medical or psychiatric illnesses.
- History of significant head trauma, alcohol or substance abuse or other medical illnesses that could cause a neurological deficit (e.g., cerebro-vascular disease) .
- Chronic medication use that, in the opinion of the Investigator, may influence or bias the clinical outcome of the trial.
- Individuals will be excluded from participation in this trial if they are judged by the Principal Investigator as having a significant impairment in their capacity for judgment or reasoning that compromise their ability to make decisions in their best interest.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test Vaccine
NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
|
NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid.
Single intramuscular 0.5 mL dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 16 µg total diphtheria toxoid.
Other Names:
Meningococcal (Groups A,C,Y and W-135-DT) Polysaccharide Conjugate Vaccine 0.5 mL dose, intramuscular.
Single dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 48 µg total diphtheria toxoid.
|
Active Comparator: US Licensed Vaccine
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
|
NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid.
Single intramuscular 0.5 mL dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 16 µg total diphtheria toxoid.
Other Names:
Meningococcal (Groups A,C,Y and W-135-DT) Polysaccharide Conjugate Vaccine 0.5 mL dose, intramuscular.
Single dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 48 µg total diphtheria toxoid.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Reactions
Time Frame: up to 6 months
|
local and systemic rates throughout the course of the study
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune Response
Time Frame: 4 and 8 weeks after injection
|
Antibody titers
|
4 and 8 weeks after injection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Sudesh Nagavalli, MD
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2011
Primary Completion (Actual)
January 1, 2013
Study Completion (Actual)
January 1, 2013
Study Registration Dates
First Submitted
November 23, 2011
First Submitted That Met QC Criteria
November 28, 2011
First Posted (Estimate)
November 30, 2011
Study Record Updates
Last Update Posted (Estimate)
January 14, 2013
Last Update Submitted That Met QC Criteria
January 11, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Infections
- Central Nervous System Infections
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Meningitis, Bacterial
- Central Nervous System Bacterial Infections
- Neisseriaceae Infections
- Meningitis, Meningococcal
- Meningitis
- Meningococcal Infections
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- JN-NM-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meningococcal Infections
-
Prof. Elizabeth MillerNovartis VaccinesCompletedMeningococcal Meningitis, Serogroup A | Meningococcal Meningitis, Serogroup B | Meningococcal Meningitis, Serogroup C | Meningococcal Meningitis, Serogroup Y | Meningococcal Meningitis, Serogroup WUnited Kingdom
-
Chiron CorporationUnknownMeningococcal Disease; Meningococcal MeningitisUnited Kingdom
-
EuBiologics Co.,LtdCompletedInfection, MeningococcalKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, Meningococcal | Meningococcal VaccinesEstonia, Germany, Spain
-
EuBiologics Co.,LtdCompletedInfection, MeningococcalKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, Meningococcal | Meningococcal VaccinesIndia, Lebanon, Philippines, Saudi Arabia
-
GlaxoSmithKlineCompletedMeningococcal Disease | Infections, MeningococcalColombia, Panama, Chile
-
GlaxoSmithKlineCompletedMeningococcal Disease | Infections, MeningococcalUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal Meningitis | Invasive Meningococcal DiseaseUnited States
-
GlaxoSmithKlineCompletedInfections, Meningococcal | Meningococcal VaccinesGermany, France
Clinical Trials on meningococcal meningitis conjugate vaccine, quadrivalent
-
National Institute of Allergy and Infectious Diseases...International Maternal Pediatric Adolescent AIDS Clinical Trials GroupCompletedHIV Infections | MeningitisUnited States, Puerto Rico
-
JN-International Medical CorporationCompletedMeningococcal Infections | Meningococcal MeningitisUnited States
-
JN-International Medical CorporationCompletedMeningococcal Infections | Meningococcal MeningitisUnited States
-
GlaxoSmithKlineCompletedMeningococcal Disease | Infections, MeningococcalUnited States
-
GlaxoSmithKlineCompletedPregnancy | Meningococcal Disease | Infections, MeningococcalUnited States
-
Public Health EnglandInstitute of Child Health; National Institute of Biological Standards and ControlCompletedPneumococcal Infections | Meningococcal InfectionsUnited Kingdom
-
Novartis VaccinesGlaxoSmithKlineCompletedMeningococcal MeningitisUnited States
-
Novartis VaccinesGlaxoSmithKlineCompletedPrevention of Meningococcal InfectionSpain, Poland
-
Novartis VaccinesCompletedPrevention of Meningococcal InfectionUnited Kingdom
-
NovartisNovartis VaccinesCompletedPrevention of Meningococcal InfectionUnited Kingdom